$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
PR Newswire —
Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This regulatory surge signals...